BioPharma Credit PLC
BioPharma Credit PLC (BOPCF) Revenue
Annual & quarterly revenue history · segment & region breakdown
BOPCF · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsBioPharma Credit PLC trailing twelve-month (TTM) revenue is $0.26B, an increase of 12.67% year-over-year from $0.14B in FY2025.
Revenue trend
2025 – 2017 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.14B | +$0.02B | +12.67% |
| 2024-12-31 | $0.12B | -$0.01B | -8.31% |
| 2023-12-31 | $0.14B | -$0.05B | -26.33% |
| 2022-12-31 | $0.18B | +$0.10B | +109.44% |
| 2021-12-31 | $0.09B | -$0.00B | -3.70% |
| 2020-12-31 | $0.09B | -$0.03B | -26.40% |
| 2019-12-31 | $0.12B | +$0.05B | +57.67% |
| 2018-12-31 | $0.08B | +$0.05B | +133.95% |
| 2017-12-31 | $0.03B | — | — |
Compare revenue vs peers
Asset ManagementCompare BOPCF revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income BioPharma Credit PLC receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
BioPharma Credit PLC reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from BioPharma Credit PLC's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
BOPCF revenue · 4 questionsBOPCF's trailing twelve-month (TTM) revenue is $0.26B. That is an increase of 12.67% year-over-year from $0.14B in FY2025.
▸ Source: FMP · BioPharma Credit PLC SEC filings · GAAP · BioPharma Credit PLC SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026